novarti biogen sma readthrough
novarti provid increment updat zolgensma sma gene
therapi novarti report patient enrol across
zolgensma clinic trial mda confer last week compani
report type sma us result consist observ
studi therapi gener well toler patient
die trial reflect much better natur histori
mortal month age zolgensma approv type set
expect may compani report expect
commerci live contract within day approv curiou
potenti price reimburs scheme could
read-through broader gene therapi space respect
zolgensma type opportun compani plan provid initi
function data type sma trial earli may
target potenti approv set consist
disclos earn continu see zolgensma
treatment choic newli diagnosed/inf sma patient
oral/it therapi play import role broader sma preval
strong uptak older type type patient popul
novarti updat compani report on-going
studi type sma patient trial expect
complet compani evalu registr path
asset data hand continu see risdiplam lead
oral splice modifi expect come market well
ahead potenti approv
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
biotechnolog compani focus
develop manufactur small molecul therapeut
address multipl area includ rare disord oncolog
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base probabl
success risdiplam stabl translarna sale post
po aadc gene therapi
grey sky valuat assum valu risdiplam
 premium
 close
spinraza launch reinforc strong commerci opportun risdiplam
report spinraza spinal muscular atrophi sale vs
consensu spinraza sale reflect commerci patient growth us
commerci patient growth exu vs biogen estim
march patient global therapi across post market
set eap clinic trial taken togeth result reconfirm view
risdiplam strong market potenti oral administr vs spinraza
everi month intrathec inject potenti differenti
peak annual sale risdiplam receiv tier royalti mid-teen
compani mention price
